Xcout IntelTISSUE REPAIR LTD competitors & alternatives
The 12 closest competitors and alternatives to TISSUE REPAIR LTD among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what TISSUE REPAIR LTD actually does, not by market-cap band.
Subscribe to see TISSUE REPAIR LTD’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About TISSUE REPAIR LTD
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
TISSUE REPAIR LTD at a glance
TISSUE REPAIR LTD is a pharmaceuticals, biotechnology & life sciences company headquartered in Chatswood, Australia. Xcout tracks 10 named people at TISSUE REPAIR LTD, including Francois Lionel Poirier (Chief Executive Officer, President & Director).
TISSUE REPAIR LTD leadership
- Francois Lionel PoirierChief Executive Officer, President & Director
- Tina Veronica FaracaExecutive Vice President & Chief Operating Officer of Natural Gas Pipelines
- Sean O'DonnellExecutive Vice President of Strategy & Corporate Development and Chief Financial Officer
- Dawn E. de LimaExecutive Vice-President of Corporate Services
- Gavin WylieVice-President of Investor Relations
- Jane BrindleVice-President of Law & Corporate Secretary
4 more named people on record for TISSUE REPAIR LTD, with roles, board committees and tenure — see the full roster →
Top 12 TISSUE REPAIR LTD competitors
Ranked by semantic similarity — how close each company is to TISSUE REPAIR LTD by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
Similar pharmaceuticals, biotechnology & life sciences company
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Tryptamine Therapeutics Limited is a public pharmaceuticals, biotechnology, and life sciences company based in Australia, trading under the ticker TYP.
Pharmaceuticals
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.
Similar pharmaceuticals, biotechnology & life sciences company
Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includes Gastrointestinal ReProgramming (GRP), a proprietary blend combining bromelain with other evidence-based ingredients, specifically formulated to target the underlying issues of human gastrointestinal conditions such as irritable bowel syndrome and inflammatory bowel disease. The firm also offers 3FDC, designed to address anxiety, stress, or depression. In the animal health sector, Anatara provides Detach for treating diarrhea in piglets, BONIFF as an enhanced dry feed formulation for weaned piglets, and ANR-pf, a unique additive for poultry drinking water. This company was founded in 2010 and is headquartered in Carlton, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
Similar pharmaceuticals, biotechnology & life sciences company
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Similar pharmaceuticals, biotechnology & life sciences company
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Similar pharmaceuticals, biotechnology & life sciences company
Starpharma Holdings Limited is a biopharmaceutical enterprise focused on the research, development, and global commercialization of dendrimer-based products for the pharmaceutical, life sciences, and other industries. Its current offerings include VivaGel, a non-antibiotic treatment and preventative measure for bacterial vaginosis. The company also provides the antiviral VivaGel condom and VIRALEZE, an antiviral nasal spray. Furthermore, Starpharma is actively progressing its DEP (dendrimer drug delivery) technology platform. This platform supports multiple oncology candidates in clinical development, such as DEP docetaxel (Phase 2), DEP cabazitaxel (Phase 2), DEP gemcitabine (Phase 1/2), and DEP irinotecan (Phase 2), all aimed at treating cancer. The DEP technology is also being applied to radiotheranostics for cancer diagnosis and therapy, Antibody Drug Conjugates (including DEP HER-2 ADC), and non-oncology programs. Additionally, DEP AZD0466 is currently in Phase 1/2 clinical trials for haematological malignancies. Founded in 1996, the company maintains its headquarters in Abbotsford, Australia.
Pharmaceuticals
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of TISSUE REPAIR LTD and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for TISSUE REPAIR LTDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →